UBS Adjusts Price Target on Pilgrim's Pride to $31 From $28, Maintains Neutral Rating
UBS has updated its price target for Pilgrim's Pride Corporation, raising it to $31 from the previous $28 while maintaining a Neutral rating.
Stocks · News reference
Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
UBS has updated its price target for Pilgrim's Pride Corporation, raising it to $31 from the previous $28 while maintaining a Neutral rating.
Jefferies has lowered its price target for Moderna, Inc. from $230 to $215.
The non-small cell lung cancer market is shifting toward precision, biomarker-guided treatment sequencing. ESMO 2026 presented Phase III data showing savolitinib plus osimertinib improved survival in MET-altered EGFR-mutated NSCLC, divarasib outperformed approved KRAS G12C inhibitors, and TROP2-directed ADCs demonstrated durable gains. The 7MM NSCLC market is projected to double from USD 33 billion in 2025 to USD 67 billion by 2036, driven by expanded screening, biomarker-driven therapies, and label expansions into earlier-stage disease.
EssilorLuxottica has selected legendary Sri Lankan cricketer Angelo Mathews to represent its eyewear brands in the local market.
The global pharmaceutical market is valued at USD 1.88 trillion in 2026 and is projected to reach USD 3.20 trillion by 2035 at a CAGR of 6.10%. Growth is concentrated in obesity and oncology therapies, with U.S. pricing deals and Section 232 tariffs reshaping manufacturing. North America holds 42% of the market, while companies with strong positions in GLP-1 medicines and cancer therapies are growing significantly faster than the market.
The article compares two semiconductor infrastructure companies: Applied Materials, which manufactures chipmaking equipment, and Marvell Technology, which designs data center networking chips. While Marvell shows faster revenue growth (30.6% vs 21.4%), Applied Materials is recommended as the safer choice due to lower valuation multiples and reduced risk from Marvell's pending $115 billion acquisition of Lumentum Holdings.